A First-in-human, Randomized, Double-blind, Placebo Controlled Combined Single-ascending Dose and Multiple-ascending Dose Study to Assess Safety, Tolerability and Pharmacokinetics of BL-1021 in Healthy Volunteers.

Trial Profile

A First-in-human, Randomized, Double-blind, Placebo Controlled Combined Single-ascending Dose and Multiple-ascending Dose Study to Assess Safety, Tolerability and Pharmacokinetics of BL-1021 in Healthy Volunteers.

Completed
Phase of Trial: Phase I

Latest Information Update: 09 May 2014

At a glance

  • Drugs BL 1021 (Primary)
  • Indications Neuropathic pain
  • Focus Adverse reactions
  • Sponsors BioLineRx
  • Most Recent Events

    • 31 Aug 2012 Results presented at the 14th World Congress on Pain.
    • 06 Dec 2011 Status changed from active, no longer recruiting to completed, according to a BioLineRx media release.
    • 13 Sep 2011 Preliminary results were reported in a BioLineRx media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top